Chargement en cours...
Is monthly retreatment with intravitreal bevacizumab (Avastin(®)) necessary in neovascular age-related macular degeneration?
PURPOSE: To report our short-term experience with bevacizumab in neovascular age-related macular degeneration (AMD) and recommend a new treatment strategy. METHODS: Retrospective chart review of 29 consecutive patients receiving 1.25 mg of intravitreal bevacizumab for AMD and completing 12 weeks of...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2010
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2861937/ https://ncbi.nlm.nih.gov/pubmed/20463798 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|